Matinas BioPharma Holdings, Inc. (MTNB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Matinas BioPharma reported revenue of $0. Net income was -$10.3M, or -$30.00 per diluted share. Operating activities generated -$7.0M of cash. At fiscal year end, Matinas BioPharma held $7.2M in total assets against $2.4M in total liabilities, including $4.0M of cash and equivalents.
Open the full interactive Matinas BioPharma financials → Quarterly statements, key ratios, valuation history and price charts.
Matinas BioPharma Key Stats
| Share Price | $2.50 |
|---|---|
| Market Cap | $1.1M |
| 52-Week Range | $0.16 – $4.47 |
| Shares Outstanding | 427,079 (basic, 2026 Q2) |
Matinas BioPharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $158,333 | $33,333 | $3.2M | $1.1M | — | $0 |
| Cost of Goods Sold | — | $24.8M | $27.8M | $24.9M | $24.6M | $7.0M |
| Gross Profit | — | -$24.7M | -$24.6M | -$23.8M | -$24.6M | -$7.0M |
| Operating Income | -$24.2M | -$24.7M | -$24.6M | -$23.8M | -$24.6M | -$7.0M |
| Pre-Tax Income | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Income Tax | — | — | — | — | -$80,000 | — |
| Net Income | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Diluted EPS | -$90.00 | -$82.50 | — | -$82.50 | -$74.70 | -$30.00 |
Matinas BioPharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.5M | -$1.9M | -$1.9M | -$1.3M |
| Diluted EPS | -$6.00 | -$0.35 | -$4.50 | -$3.15 |
Matinas BioPharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.4M | $21.0M | $6.8M | $4.8M | $7.3M | $4.0M |
| Current Assets | $61.6M | $51.0M | $34.5M | $15.5M | $8.0M | $4.1M |
| Total Assets | $71.0M | $61.3M | $44.8M | $25.1M | $12.6M | $7.2M |
| Current Liabilities | $3.6M | $4.3M | $4.3M | $2.6M | $2.7M | $1.5M |
| Total Liabilities | $7.2M | $8.8M | $8.2M | $5.9M | $5.1M | $2.4M |
| Shareholders' Equity | $63.7M | $52.5M | $36.6M | $19.2M | $7.6M | $4.8M |
Matinas BioPharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$17.4M | -$15.2M | -$19.2M | -$15.3M | -$15.9M | -$7.0M |
| Cash From Investing | -$40.7M | $16.8M | $4.9M | $13.2M | $9.2M | $335,000 |
| Cash From Financing | $48.0M | $7.0M | $79,000 | -$7,000 | $9.2M | $3.4M |
| Free Cash Flow | -$17.4M | -$15.5M | -$20.0M | -$15.5M | -$16.1M | — |
Figures from Matinas BioPharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Matinas BioPharma financials page for every line item.
Matinas BioPharma Company Profile
| Ticker | MTNB |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Bedminster, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001582554 |
Frequently Asked Questions
What was Matinas BioPharma's revenue in fiscal 2025?
Matinas BioPharma (MTNB) reported revenue of $0 for fiscal 2025.
What is Matinas BioPharma's annual revenue history?
Matinas BioPharma's annual revenue by fiscal year: 2020: $158,333; 2021: $33,333; 2022: $3.2M; 2023: $1.1M; 2025: $0.
What was Matinas BioPharma's net income in fiscal 2025?
Matinas BioPharma reported net income of -$10.3M for fiscal 2025.
What was Matinas BioPharma's earnings per share (EPS) in fiscal 2025?
Matinas BioPharma's diluted EPS was -$30.00 for fiscal 2025 (adjusted for any later stock splits).
What was Matinas BioPharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), Matinas BioPharma reported revenue of $0.
How many shares of Matinas BioPharma are outstanding?
Matinas BioPharma reported a weighted average of 427,079 basic shares outstanding in 2026 Q2.
What is Matinas BioPharma's market cap?
Based on its latest closing price, Matinas BioPharma (MTNB) has a market capitalization of about $1.1M.
When does Matinas BioPharma's fiscal year end?
Matinas BioPharma's fiscal year end, as registered with the SEC, is December 31.
Where is Matinas BioPharma headquartered?
Matinas BioPharma lists its business address in Bedminster, New Jersey in its SEC filings.